Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

CLINICA 100 TOP 10: Danaher

This article was originally published in Clinica

Executive Summary

Edging its way into the Top 10 for the first time is Danaher. The company moved up one position to No 10 in our Clinica 100 league table*. It continues to be No 2 in the IVD list, behind Roche. Danaher was involved in one of 2015’s mega-mergers, making its biggest buy ever with a $13.8bn deal for filtration technology specialist Pall. The companies serve not only the life sciences market (Danaher more so than Pall) but also other non-healthcare related industries (Pall more so than Danaher). With the acquisition of Pall, the bulked up Danaher plans to split into two publicly listed companies – the concern that will retain the Danaher name will encompass Danaher’s life sciences, diagnostics and dental segments and the other concern will consists of the water quality and product identification platforms and most of the acquired Pall businesses.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst